The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
297
Sickle Cell Crisis Rate
Time frame: 52 weeks
Time to First, Second, and Third Crisis
Time frame: 52 Weeks
Maximum Crisis Morbidity Ranking
Time frame: 52 Weeks
Efficacy Related Laboratory Parameters
Time frame: 52 Weeks
Quality of Life
Time frame: 52 Weeks
Health Economics
Time frame: 52 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
Davis, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Oakland, California, United States
Unnamed facility
Denver, Colorado, United States
Unnamed facility
Hartford, Connecticut, United States
Unnamed facility
Washington D.C., District of Columbia, United States
Unnamed facility
Holly Hill, Florida, United States
Unnamed facility
Hollywood, Florida, United States
...and 39 more locations